Performance of Rapid Antigen Tests Based on Symptom Onset and Close Contact Exposure: A secondary analysis from the Test Us At Home prospective cohort study

Authors: Carly Herbert BA¹, Bigi Wang PhD^{1,2}, Honghuang Lin^{1,2}, Nathaniel Hafer³, Caitlin Pretz 3 MS¹, Pamela Stamegna¹, Seanan Tarrant BA¹, Paul Hartin BS¹, Julia Ferranto BS¹, Stephanie 4 Behar BA¹, Colton Wright MS¹, Taylor Orwig BS¹, Thejas Suvarna BBA, BS⁴, Emma Harman 5 MPH⁴, Summer Schrader BA⁴, Chris Nowak BA⁴, Vik Kheterpal MD⁴, Elizabeth Orvek MS⁵, 6 Steven Wong BA, Adrian Zai MD, PhD, Bruce Barton PhD², Ben Gerber MD, MPH⁵, Stephenie 7 C Lemon PhD², Andreas Filippaios MD¹, Kylie D'Amore¹, Laura Gibson MD, Sharone Greene 8 MD, Sakeina Howard-Wilson DO¹, Andres Colubri PhD⁶, Chad Achenbach MD, MPH⁷, Robert 9 Murphy MD⁷, William Heetderks PhD⁸, Yukari C Manabe MD⁹, Laurel O'Connor MD¹⁰, Nisha 10 Fahey DO, ScM^{1,5,11}, Katherine Luzuriaga MD^{3,12}, John Broach MD, MPH, MBA¹⁰, David D 11

- 12 McManus MD, ScM^{1,2,13}, Apurv Soni MD, PhD^{1,2,5}
- 13
- 14 Affiliations:
- ¹⁵ ¹Program in Digital Medicine, Department of Medicine, University of Massachusetts Chan
- 16 Medical School, Worcester, MA, USA
- ²Division of Health System Science, Department of Medicine, University of Massachusetts Chan
 Medical School, Worcester, MA, USA
- ¹⁹ ³University of Massachusetts Center for Clinical and Translational Science, University of
- 20 Massachusetts Chan Medical School, Worcester, MA, USA
- ⁴CareEvolution, LLC, Ann Arbor, MI, USA
- ⁵Department of Population and Quantitative Health Sciences, University of Massachusetts Chan
 Medical School, Worcester, MA, USA
- ⁶Department of Microbiology and Physiological Systems, University of Massachusetts Chan
 Medical School, Worcester, MA, USA
- ⁷Division of Infectious Disease, Department of Medicine, Havey Institute for Global Health,
- 27 Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
- ⁸National Institute of Biomedical Imaging and Bioengineering, NIH, via contract with Kelly
 Services, Bethesda, MD, USA
- ⁹Division of Infectious Disease, Department of Medicine, Johns Hopkins University School of
 Medicine, Baltimore, MD, USA
- ¹⁰Department of Emergency Medicine, University of Massachusetts Chan Medical School,
 Worcester, MA, USA
- ¹¹Department of Pediatrics, University of Massachusetts Chan Medical School, Worcester, MA,
 USA
- ¹²Program in Molecular Medicine, University of Massachusetts Chan Medical School,
- 37 Worcester, MA, USA

- ¹³Division of Cardiology, Department of Medicine, University of Massachusetts Chan Medical
- 39 School, Worcester, MA, USA

- 41 Corresponding author:
- 42 Apurv Soni, MD PhD
- 43 55 Lake Avenue North
- 44 Worcester, MA 01605
- 45 Apurv.soni@umassmed.edu

- .,

66

67 Abstract

- 68 Background: The performance of rapid antigen tests for SARS-CoV-2 (Ag-RDT) in temporal
- relation to symptom onset or exposure is unknown, as is the impact of vaccination on this
- 70 relationship.
- 71 **Objective:** To evaluate the performance of Ag-RDT compared with RT-PCR based on day after 72 symptom onset or exposure in order to decide on 'when to test'.

Design, Setting, and Participants: The Test Us at Home study was a longitudinal cohort study that enrolled participants over 2 years old across the United States between October 18, 2021 and February 4, 2022. All participants were asked to conduct Ag-RDT and RT-PCR testing every 48 hours over a 15-day period. Participants with one or more symptoms during the study period were included in the Day Post Symptom Onset (DPSO) analyses, while those who reported a COVID-19 exposure were included in the Day Post Exposure (DPE) analysis.

- Exposure: Participants were asked to self-report any symptoms or known exposures to SARS CoV-2 every 48-hours, immediately prior to conducting Ag-RDT and RT-PCR testing. The first
 day a participant reported one or more symptoms was termed DPSO 0, and the day of exposure
 was DPE 0. Vaccination status was self-reported.
- was DPE 0. Vaccination status was self-reported.
- 84 Main Outcome and Measures: Results of Ag-RDT were self-reported (positive, negative, or
- 85 invalid) and RT-PCR results were analyzed by a central laboratory. Percent positivity of SARS-
- CoV-2 and sensitivity of Ag-RDT and RT-PCR by DPSO and DPE were stratified by vaccination
 status and calculated with 95% confidence intervals.
- **Results:** A total of 7,361 participants enrolled in the study. Among them, 2,086 (28.3%) and 546
- (7.4%) participants were eligible for the DPSO and DPE analyses, respectively. Unvaccinated
 participants were nearly twice as likely to test positive for SARS-CoV-2 than vaccinated
- 91 participants in event of symptoms (PCR+: 27.6% vs 10.1%) or exposure (PCR+: 43.8% vs.
- 22.2%). The highest proportion of vaccinated and unvaccinated individuals tested positive on
- DPSO 2 and DPE 5-8. Performance of RT-PCR and Ag-RDT did not differ by vaccination
- status. Ag-RDT detected 78.0% (95% Confidence Interval: 72.56-82.61) of PCR-confirmed
- 95 infections by DPSO 4. For exposed participants, Ag-RDT detected 84.9% (95% CI: 75.0-91.4) of
- 96 PCR-confirmed infections by day five post-exposure (DPE 5).
- 97 **Conclusions and Relevance:** Performance of Ag-RDT and RT-PCR was highest on DPSO 0-2
- 98 and DPE 5 and did not differ by vaccination status. These data suggests that serial testing 99 remains integral to enhancing the performance of Ag-RDT
- remains integral to enhancing the performance of Ag-RDT.
- 100
- 101
- 102
- 103
- 104
- 105
- 106

107

108

109 Introduction:

110 Rapid antigen tests (Ag-RDTs) are commonly used to diagnose COVID-19 due to their 111 availability over-the-counter for home use, relatively low cost, and ability to return results in 15-20 minutes.¹⁻³ Previous work has informed the FDA guidance on *testing frequency* to minimize 112 the risk of false negative tests in symptomatic as well as asymptomatic individuals.⁴ However, 113 114 important questions remain about *when to begin testing*, particularly among those with symptoms or after close contact with an infected person.^{4,5} Similarly, our understanding of Ag-115 RDT performance by time past exposure is limited.^{6–8} Understanding Ag-RDT performance 116 117 change over the symptom course and in relation to SARS-CoV-2 exposure is crucial to guide optimal use of diagnostics for risk assessment. 118

119 Several prior studies have examined Ag0RDT performance when used serially, but these studies predate the arrival of the Omicron variants in the United States and widespread 120 vaccination coverage.^{9,10} Currently, approximately four in every five U.S. adults have received at 121 least one dose of a SARS-CoV-2 vaccine.¹¹ Vaccination has been associated with changes in 122 the signs and symptoms of SARS-CoV-2 infection, including fewer symptoms and a higher 123 likelihood of asymptomatic infections.¹² The performance of molecular diagnostics, including 124 125 reverse transcriptase polymerase chain reaction (RT-PCR), and Ag-RDTs is closely related to 126 detectable viral load; therefore, it is important to determine whether changes in viral dynamics 127 and symptomology due to vaccination have an impact on diagnostic performance.

Using data from Test Us at Home, a prospective cohort study that enrolled participants from throughout the United States, we examined paired serial Ag-RDT and molecular testing to determine how relative sensitivities of Ag-RDT and RT-PCR tests vary by day past symptom onset and exposure and how these findings vary based on vaccination status. The results of this study will inform pragmatic use of Ag-RDT at-home tests to detect SARS-CoV-2.

133 Methods:

134 **Study Population:**

135 In this analysis, we used data from the Test Us at Home study, a longitudinal cohort study that 136 evaluated the performance of serial use of Aq-RDTs for detection of COVID-19 among asymptomatic individuals.⁴ The Test Us at Home study enrolled participants ages 2 years and 137 138 older across the United States between October 18, 2021 and February 4, 2022. This study was 139 approved by the WIRB-Copernicus Group (WCG) Institutional Review Board (20214875). Only 140 participants who completed at least one Ag-RDT or RT-PCR were included in this analysis. Participants were included in the Day Post Symptom Onset (DPSO) analyses if they self-141 142 reported any symptoms during the study period (Figure 1). Participants who had a RT-PCR+ result more than 14 days before or after symptom onset were excluded, as these symptoms 143 were assumed to be unrelated to the observed infection.¹³ Participants who reported 144 145 experiencing a COVID-19 exposure during the study were included in the Day Post Exposure 146 (DPE) analysis. Participants with an index RT-PCR+ result more than 14 days after the reported exposure were excluded from the DPE analyses. 147 All Test Us at Home participants were asked to conduct Ag-RDT and RT-PCR testing every 2 148 149 days over a 15-day period. Participants were asked if they had any symptoms in the last 48 150 hours or any known exposures to SARS-CoV-2 at the beginning of each testing session. During 151 each testing session, two anterior nasal swabs were collected by the participant; one swab was 152 used for performing an Ag-RDT at home, while the other swab was sent to a central laboratory 153 for RT-PCR testing. All study activities and questionnaires were conducted through a custom 154 study app. Additional details about the study design, protocol, and participants are described

155

elsewhere.4,14

156 Measures:

Symptoms: Participants self-reported symptoms (fever, body aches, fatigue, rash, nausea, abdominal pain, diarrhea, loss of smell, runny nose, cough, headache, or other) during each testing period immediately prior to using the Ag-RDT (every 48 hours). The first day that a participant reported 1 or more symptoms was termed DPSO 0.

161 Close-Contact Exposure: Participants self-reported close-contact exposures to COVID-19 at

the time of baseline study enrollment and before each testing period. An exposure was defined

as being within 6 feet of an infected person without a mask for at least 15 minutes over a 24-

hour period. DPE 0 was defined as the first day of the reported exposure.

165 Vaccination Status and Previous Infections: Vaccination status and history of previous

166 SARS-CoV-2 infection was self-reported during the enrollment survey. Vaccination status was

167 operationalized into two groups: vaccinated (≥1 dose) and unvaccinated (0 doses). Previous

168 infections with SARS-CoV-2 were self-reported.

169 Molecular Testing (RT-PCR): Molecular comparator RT-PCR results were based on a

170 combination of molecular test results for the detection of SARS-Cov-2 infection.⁴ Cycle

threshold (Ct) values for the E-gene from RT-PCR were used to quantify viral load.

Rapid antigen test positivity: Participants were asked to provide an interpretation of each Ag-172 173 RDT (positive, negative, or invalid) and upload a picture of the test result to the study app. All 174 self-reported positive tests were confirmed by study coordinators using the uploaded images. 175 Data Analysis: Percent positivity and cumulative positivity of all symptomatic and/or exposed 176 participants were calculated for RT-PCR and Ag-RDT by DPSO and DPE and stratified by vaccination status with 95% confidence intervals using Wilson's method.¹⁵ Cumulative positivity 177 178 was defined as the number of participants with at least one positive test result over the number of participants who had taken at least one test until each DPSO and DPE. Sensitivity analysis 179 180 was performed to assess whether findings differed between partially vaccinated (1 dose) and

- fully vaccinated (2+ doses) participants. All analyses were conducted using R software package
 version 4.2.1.
- 183 **Results**:
- 184 Characteristics of Symptomatic and Exposed Participants
- A total of 2,086 of the 7,361 total Test Us At Home participants (28.3%) reported symptoms
- associated with COVID-19 infection and were eligible for the DPSO analysis; 546 participants
- 187 reported a close-contact exposure and were eligible for the DPE analysis (Figure 1).
- Approximately 10% of vaccinated and 20% of unvaccinated participants reported at least one
- previous SARS-CoV-2 infection (Table 1). Participants less than 18 years old comprised 36.9%
- and 47.6% of unvaccinated participants in the DPSO and DPE analyses, respectively, while
- they comprised 7.2% and 10.6% of vaccinated individuals. The majority of vaccinated
- 192 participants (1677, 93.8%) had received 2+ doses of a SARS-CoV-2 vaccine.
- 193 Percent Positivity of Ag-RDT and Molecular Tests by Day Past Symptom Onset among
- 194 Vaccinated and Unvaccinated Individuals
- Among 2,086 participants that reported at least one symptom, 12.5% tested positive by RT-PCR
- during the study (Table 1; Supplemental Figure 1a). Significantly fewer symptomatic vaccinated
- 197 participants tested positive for SARS-CoV-2 during the study period compared to unvaccinated
- 198 participants (Unvaccinated: PCR+: 27.6% vs Vaccinated PCR+: 10.1%; Unvaccinated Ag-
- 199 RDT+: 25.3% vs. Vaccinated Ag-RDT+: 10.9%) (Supplemental Figure 1b). Trends were similar
- among those who were fully vaccinated (2+ doses) and partially vaccinated (1 dose)
- 201 (Supplemental Figure 1c). The highest proportion of vaccinated and unvaccinated symptomatic
- 202 individuals tested positive on DPSO 2 (Figure 2a, 2b).
- 203 Percent positivity of Rapid Antigen Tests and Molecular Tests by Day Past Exposure among
- 204 Vaccinated and Unvaccinated Individuals

205 Of the 546 participants who reported a close-contact exposure during the study, 17.6% tested 206 positive by RT-PCR (Table 1; Supplemental Figure 1d). More than 50% of vaccinated and 207 unvaccinated individuals with close contact exposures also reported COVID-related symptoms 208 during the study (Table 1). Exposed unvaccinated participants tested positive for SARS-CoV-2 209 twice as often than exposed vaccinated participants, on both RT-PCR and Ag-RDT 210 (Unvaccinated PCR+: 43.8% vs. Vaccinated PCR+: 22.2%; Unvaccinated Ag-RDT+: 44.3% vs. 211 Vaccinated Ag-RDT+: 23.4%) (Supplemental Figure 1e). The cumulative positivity of exposed 212 participants was conditioned on symptom status, such that exposed individuals with symptoms 213 were much more likely to test positive within the first week since exposure (<DPE 6) than participants who were exposed but did not have symptoms on the day of testing (Supplemental 214 215 Figure 2). Percent positivity was highest on DPE 5 through DPE 8, irrespective of vaccination or 216 symptom status (Figure 3a, 3b). 217 Diagnostic Performance by Timing of Symptom Onset and Exposure We did not observe significant differences in the performance of RT-PCR and Ag-RDT by 218 219 vaccination status by DPSO or DPE (Figure 2, Figure 3), and Ct values did not differ 220 significantly between vaccinated and unvaccinated participants (Supplemental Figure 3). Among 221 both vaccinated and unvaccinated participants, Ct value was lowest (i.e., highest viral burden) 222 at DPSO 0-2 and DPE 5 (Supplemental Figure 3). Among symptomatic participants, RT-PCR 223 detected 81.6% (95% CI: 76.2-85.9) of all PCR-confirmed infections on DPSO 0, while Ag-RDT 224 detected 59.0% (95% CI: 52.9-64.8) of PCR-confirmed infections at this time (Figure 2c, 2d, 225 Supplemental Table 1). Aq-RDT detected 79.9% (95% CI: 73.4-85.1) of vaccinated PCR-226 confirmed infections and 73.8% (95% CI: 63.2-82.1) of unvaccinated PCR-confirmed infections 227 by DPSO 4 (Figure 2c). For exposed participants, RT-PCR and Ag-RDT detected over 94.7% 228 (95% CI: 87.1-97.9) and 84.9% (95% CI: 75.0-91.4) of PCR-confirmed infections on day five post-exposure (DPE 5), respectively (Figure 3c, 3d, Supplemental Table 2). 229

230 **Discussion:**

231 In this study, we report the performance of nasal-swab Ag-RDT and molecular testing by 232 time since symptom onset and time since exposure among individuals who were and were not 233 vaccinated against SARS-CoV-2. Our study highlights three important findings: 1) we report that 234 the real-world performance of Ag-RDT and RT-PCR peaked at DPSO 0-2 for symptomatic 235 individuals and on DPE 5 for exposed individuals; 2) we show that the performance of Ag-RDT 236 tests is similar among vaccinated and unvaccinated participants, likely because the viral peak did not differ between these groups; and 3) we demonstrate real-world evidence that 237 238 participants who were vaccinated had significantly lower likelihood of testing positive on RT-239 PCR or Ag-RDT after an exposure than those who were unvaccinated. Taken together, these 240 findings reinforce the importance of Ag-RDT tests for detection of SARS-CoV-2 virus and 241 highlight the need for serial testing after symptom onset or exposure, as well as indicate the 242 continued importance of vaccination.

As the pandemic enters its third year, use of COVID-19 diagnostics has shifted away 243 244 from general screening and mandated testing towards personal risk assessment, with most people using Ag-RDT in response to acute symptoms or COVID-19 exposure.¹⁶ It is increasingly 245 246 important to advise individuals on the timing of Ag-RDT use, to facilitate accurate test 247 interpretation and minimize false-negative results. The present results reinforce the importance 248 of serial testing when individuals are either symptomatic or exposed to SARS-CoV-2, in line with 249 our previous recommendations (i.e., symptomatic individuals should perform two Ag-RDT 48 250 hours apart and asymptomatic individuals should perform three Ag-RDT 48 hours apart each).⁴ 251 In case of symptoms, we recommend that individuals test with Aq-RDT on DPSO 2 and 4 to 252 minimize the risk of false negative results. Further, to decrease transmission of SARS-CoV-2, 253 individuals should isolate until DPSO 4, regardless of a negative test result on DPSO 2. For symptomatic individuals in our study, close to 80% of PCR-confirmed infections were detected 254

255 by Ag-RDT by DPSO 4. Among exposed participants, Ag-RDT detected 5 in 6 PCR-confirmed infections by DPE 5, regardless of symptomatic status. Few new cases of SARS-CoV-2 were 256 257 detected following DPE 6. These results were consistent among vaccinated and unvaccinated 258 participants and support the CDC recommendations to isolate for 5 days post-exposure.¹⁷ A 259 previous study of 225 individuals with PCR-confirmed SARS-CoV-2 infections similarly found 260 that RT-PCR had a positivity rate of approximately 60% on the day of illness onset (defined as 261 symptom onset among symptomatic individuals and first RT-PCR+ test among asymptomatic individuals).¹⁰ However, these investigators found that PCR-positivity and Ag-RDT-positivity 262 peaked on day 3 and 4 past illness onset, which differs from our own results showing that that 263 diagnostic performance peaked on DPSO 0 and 2. The observed difference may be explained 264 by the emergence of new variants, as over 75% of infections in our study were due to the 265 266 Omicron variant, which has a shorter incubation period than all previous SARS-CoV-2 strains.^{18,19} This discrepancy between results emphasizes the importance of re-evaluation of 267 268 SARS-CoV-2 diagnostic performance and testing advisories as new SARS-CoV-2 variants 269 continue to arise.

270 To our knowledge, most studies evaluating treatment effects of vaccination for SARS-271 CoV-2 has demonstrated vaccine's efficacy for preventing severe disease, hospitalization, and 272 death from COVID-19, but few have demonstrated efficacy for preventing infections. Previous 273 studies have been limited in their ability to determine the impact of vaccination on susceptibility and transmission of COVID-19.²⁰⁻²² In our study, unvaccinated individuals exposed to SARS-274 275 CoV-2 had nearly twice the likelihood of infection compared to exposed vaccinated individuals. 276 This finding indicates that SARS-CoV-2 vaccination may indeed prevent against infection following exposure to the virus. This is especially noteworthy, as breakthrough infections due to 277 the Omicron variant have become common.²³ Our finding provides real-world data that is similar 278 279 to previous reports based on passive data collection through electronic medical records and

280 workplace studies, which suggest that even one dose of vaccination decreases the risk of infection from SARS-CoV-2.²⁴⁻²⁶ In contrast to those studies, we account for both RT-PCR and 281 Ag-RDT results in this study, and all participants, regardless of vaccination status, used the 282 283 same diagnostics and procedures to screen for infection every 48 hours, which allowed for 284 rigorous evaluation of the efficacy of vaccination for preventing infection after exposure. It is 285 important to note that, among those who acquired infection, vaccination status did not affect RT-286 PCR or Ag-RDT tests' sensitivity or viral dynamics, thus not requiring different testing strategies 287 based on vaccination status.

288 Despite differences in the rates of infection among vaccinated and unvaccinated participants, once infected, peak viral load did not differ between vaccinated and unvaccinated 289 individuals, consistent with previous reports.^{27,28} This also helps to explain why we did not 290 291 observe a significant difference in performance of Ag-RDT among vaccinated and unvaccinated 292 individuals, as performance of Aq-RDTs is tightly correlated with viral load, with Aq-RDT diagnostic performance showing major declines when Ct > 30.¹⁸ Vaccinated and unvaccinated 293 individuals did not differ in magnitude nor timing of viral load with relation to DPSO and DPE; 294 therefore, no differences in diagnostic performance would be expected. However, while 295 296 magnitude and timing of peak viral load did not differ between vaccinated and unvaccinated 297 individuals, previous studies have shown that the duration of infectiousness may differ, with unvaccinated individuals showing prolonged infectiousness. Together, these results add to the 298 299 evidence that vaccination against SARS-CoV-2 may decrease the risk of subsequent infection. 300 but more studies are needed to understand the impact of vaccination on levels of infectiousness, as a function of viral load, during SARS-CoV-2 infection. 301

302 Study Strengths and Limitations:

This is one of the first studies to analyze the diagnostic performance of RT-PCR and Ag-RDT for COVID-19 based on days past acute symptom onset or exposure to an individual infected

with SARS-CoV-2. Our study assessed serial paired longitudinal data to evaluate the
 performance of Ag-RDT and RT-PCR over the duration of infection using a large nationwide
 sample of children and adults. This is also, to the best of our knowledge, the first study to
 quantify time from exposure to Ag-RDT positivity.

- 309 Our study has limitations that need to be considered when interpreting our findings. Paired Ag-
- RDT and RT-PCR testing, as well as symptom trackers, were completed by participants every
- 48-hours. Assessing diagnostic performance at a finer temporal resolution might be useful in
- future studies. Symptoms, exposures, and Ag-RDT results were based on participant self-
- 313 report. However, all positive Ag-RDT results were verified by research coordinators using
- images of the test strip that were uploaded by participants. In this analysis, we categorized
- anyone who received 1 or more vaccines for SARS-CoV-2 as vaccinated due to sample size
- limitations; therefore, there may be heterogeneity in the vaccine responses and immunity within
- this group. However, sensitivity analyses showed that results were consistent when those with 1
- vaccination dose and 2+ doses were examined separately.

319 **Conclusions**:

- In conclusion, this study supports testing immediately after symptom onset and between 3-5
- 321 days after exposure for optimal detection of SARS-CoV2 virus. Our findings suggest that
- 322 vaccination prevents SARS-CoV-2 infection but not does not affect the performance of Ag-RDT
- or RT-PCR tests. Taken in sum, our results highlight the effectiveness of vaccination and serial
- testing in the context of symptom onset or close contact as public health strategies to manage
- 325 transmission of SARS-CoV-2 virus.
- 326

Competing Interest Statement: VK is principal, and TS, SS, CN, and EH are employees of the
 health care technology company CareEvolution, which was contracted to configure the
 smartphone study app, provide operational and logistical support, and collaborate on overall
 research approach. DDM reports consulting and research grants from Bristol-Myers Squibb and

Pfizer, consulting and research support from Fitbit, consulting and research support from

Flexcon, research grant from Boehringer Ingelheim, consulting from Avania, non-financial

research support from Apple Computer, consulting/other support from Heart Rhythm Society.

334 YCM has received tests from Quanterix, Becton-Dickinson, Ceres, and Hologic for research-

related purposes, consults for Abbott on subjects unrelated to SARS-CoV-2, and receives

funding support to Johns Hopkins University from miDiagnostics. LG is on a scientific advisory board for Moderna on projects unrelated to SARS-CoV-2. AS receives non-financial support

board for Moderna on projects unrelated to SARS-CoV-2. AS receives non-financial support
 from CareEvolution for collaborative research activities. Additional authors declare no financial

- aron Care volution for conaborative research activities. Additional authors decia
 or non-financial competing interests.
- 340

341 **Funding Statement**: This study was funded by the NIH RADx Tech program under

342 3U54HL143541-02S2 and NIH CTSA grant UL1TR001453. The views expressed in this

343 manuscript are those of the authors and do not necessarily represent the views of the National

Institute of Biomedical Imaging and Bioengineering; the National Heart, Lung, and Blood

Institute; the National Institutes of Health, or the U.S. Department of Health and Human

346 Services. Salary support from the National Institutes of Health U54HL143541, R01HL141434,

- 347 R01HL137794, R61HL158541, R01HL137734, U01HL146382 (AS, DDM), U01AG068221 (HL),
- 348 U54EB007958-13 (YCM, MLR), AI272201400007C, UM1AI068613 (YCM), U54EB027049 and
- 349 U54EB027049-02S1 (CJA, RLM).

350 Acknowledgment: We are grateful to our study participants and to our collaborators from the National Institute of Health (NIBIB and NHLBI) who provided scientific input into the design of 351 this study and interpretation of our results, but could not formally join as co-authors due to 352 353 institutional policies and to the Food and Drug Administration (Office of In Vitro Diagnostics and Radiological Health) for their involvement in the primary TUAH study. We received meaningful 354 355 contributions from Drs. Bruce Tromberg, Jill Heemskerk, Felicia Qashu, Dennis Buxton, Erin Iturriaga, Jue Chen, Andrew Weitz, and Krishna Juluru. We are thankful to county health 356 357 departments across the country who helped with recruitment for this siteless study by spreading 358 the word in their networks.

- 1. Crozier A, Rajan S, Buchan I, McKee M. Put to the test: Use of rapid testing technologies for Covid-19. *The BMJ*. 2021;372. doi:10.1136/bmj.n208
- 2. Peeling RW, Olliaro PL, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen tests: promises and challenges. *Lancet Infect Dis.* 2021;21(9). doi:10.1016/S1473-3099(21)00048-7
- 3. Drain PK. Rapid Diagnostic Testing for SARS-CoV-2. *New England Journal of Medicine*. 2022;386(3):264-272. doi:10.1056/NEJMCP2117115
- Soni A, Herbert C, Lin H, et al. Performance of Screening for SARS-CoV-2 using Rapid Antigen Tests to Detect Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infection: findings from the Test Us at Home prospective cohort study. *medRxiv*. Published online August 6, 2022:2022.08.05.22278466. doi:10.1101/2022.08.05.22278466
- 5. Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. *PLoS Med*. 2021;18(8):e1003735-. https://doi.org/10.1371/journal.pmed.1003735
- 6. Torres I, Poujois S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen test (Panbio[™] COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. *Clinical Microbiology and Infection*. 2021;27(4):636.e1-636.e4. doi:10.1016/J.CMI.2020.12.022
- Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains A Systematic Review and Meta-analysis Key Points + Supplemental content. JAMA Netw Open. 2022;5(8):2228008. doi:10.1001/jamanetworkopen.2022.28008
- Robinson ML, Mirza A, Gallagher N, et al. Limitations of Molecular and Antigen Test Performance for SARS-CoV-2 in Symptomatic and Asymptomatic COVID-19 Contacts. *J Clin Microbiol*. 2022;60(7). doi:10.1128/JCM.00187-22/SUPPL_FILE/JCM.00187-22-S0001.PDF
- Smith RL, Gibson LL, Martinez PP, et al. Longitudinal Assessment of Diagnostic Test Performance Over the Course of Acute SARS-CoV-2 Infection. *J Infect Dis*. 2021;224(6):976-982. doi:10.1093/infdis/jiab337
- Chu VT, Schwartz NG, Donnelly MAP, et al. Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection. JAMA Intern Med. 2022;182(7):701-709. doi:10.1001/jamainternmed.2022.1827
- 11. Vaccines for COVID-19 | CDC. Accessed October 13, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html
- 12. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect Dis*. 2022;22(1):43-55. doi:10.1016/S1473-3099(21)00460-6
- Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. https://doi.org/107326/M20-0504. 2020;172(9):577-582. doi:10.7326/M20-0504

- 14. Soni A, Herbert C, Pretz C, Stamegna P, Filippaios A. Finding a Needle in the Haystack: Design and Implementation of a Digital Site-less Clinical Study of Serial Rapid Antigen Testing to Identify Asymptomatic SARS-CoV-2 Infection. *medRxiv*. Published online August 8, 2022.
- 15. Wilson EB. Probable Inference, the Law of Succession, and Statistical Inference. *J Am Stat Assoc*. 1927;22(158):209-212. doi:10.1080/01621459.1927.10502953
- Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests United States, August 23, 2021–March 12, 2022. *MMWR Morb Mortal Wkly Rep.* 2022;71(13):489-494. doi:10.15585/MMWR.MM7113E1
- 17. CDC streamlines COVID-19 guidance to help the public better protect themselves and understand their risk. CDC Newsroom Releases. Published August 11, 2022. Accessed December 20, 2022. https://www.cdc.gov/media/releases/2022/p0811-covid-guidance.html
- Soni A, Herbert C, Filippaios A, et al. Comparison of Rapid Antigen Tests' Performance Between Delta and Omicron Variants of SARS-CoV-2. Ann Intern Med. Published online October 11, 2022. doi:10.7326/M22-0760
- Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. *JAMA Netw Open*. 2022;5(8):e2228008-e2228008. doi:10.1001/jamanetworkopen.2022.28008
- 20. el Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *New England Journal of Medicine*. 2021;385(19):1774-1785. doi:10.1056/NEJMOA2113017/SUPPL_FILE/NEJMOA2113017_DATA-SHARING.PDF
- 21. Tenforde MW, Self WH, Naioti EA, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1156-1162. doi:10.15585/MMWR.MM7034E2
- 22. Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *Lancet*. 2021;397(10282):1351-1362. doi:10.1016/S0140-6736(21)00628-0
- Birhane M, Bressler S, Chang G, et al. COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(21):792-793. doi:10.15585/MMWR.MM7021E3
- Buchan SA, Chung H, Brown KA, et al. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. JAMA Netw Open. 2022;5(9):e2232760-e2232760. doi:10.1001/JAMANETWORKOPEN.2022.32760
- Ioannou GN, Bohnert ASB, O'Hare AM, et al. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era. *https://doi.org/107326/M22-1856*. Published online October 11, 2022. doi:10.7326/M22-1856
- 26. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread

Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(34):1163-1166. doi:10.15585/MMWR.MM7034E3

- 27. Boucau J, Marino C, Regan J, et al. Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection. *New England Journal of Medicine*. 2022;387(3):275-277. doi:10.1056/NEJMc2202092
- 28. Ke R, Martinez PP, Smith RL, et al. Longitudinal Analysis of SARS-CoV-2 Vaccine Breakthrough Infections Reveals Limited Infectious Virus Shedding and Restricted Tissue Distribution. *Open Forum Infect Dis.* 2022;9(7):ofac192. doi:10.1093/ofid/ofac192

Tables and Figures:

Table 1: Characteristics of Vaccinated and Unvaccinated Participants included in Analyses

		Included in DPSO analysis		Included in DPE analysis	
		(n= 2086)		(n=546)	
		Vaccinated	Unvaccinated	Vaccinated	Unvaccinated
		(n=1788)	(n=298)	(n=464)	(n=82)
Confirmed RT-PCR+:					
n	(%)	179 (10.0)	81 (27.2)	64 (13.8)	32 (39.0)
Symptomatic: n (%)		1788 (100.0)	298 (100.0)	233 (50.2)	45 (54.9)
Ρ	revious Infections				
	None	1608 (89.9)	235 (78.9)	419 (90.3)	64 (78.0)
	1	165 (9.2)	57 (19.1)	38 (8.2)	17 (20.7)
	2+	15 (0.8)	6 (2.0)	7 (1.5)	1 (1.2)
Ρ	articipant Age				
()	<u>/</u> ears): n (%)				
	<18 years	128 (7.2)	110 (36.9)	49 (10.6)	39 (47.6)
	18-44	1158 (64.8)	140 (47.0)	272 (58.6)	31 (37.8)
	45-64	401 (22.4)	43 (14.4)	129 (27.8)	10 (12.2)
	≥65 years	101 (5.6)	5 (1.7)	14 (3.0)	2 (2.4)
G	ender: n (%)				
	Men	458 (25.6)	93 (31.2)	145 (31.2)	34 (41.5)
	Women	1263 (70.6)	199 (66.8)	309 (66.6)	45 (54.9)
	Transgender	4 (0.2)	0 (0.0)	0 (0.0)	0 (0.0)
	Non-binary	51 (2.9)	1 (0.3)	9 (1.9)	0 (0.0)
	Missing	12 (0.7)	5 (1.7)	1 (0.2)	3 (3.7)
Race: n (%)					
	White	1451 (81.2)	252 (84.6)	361 (77.8)	72 (87.8)
	Asian	84 (4.7)	5 (1.7)	32 (6.9)	1 (1.2)
	Black/African-				
	American	49 (2.7)	14 (4.7)	14 (3.0)	3 (3.7)
	Native				
	American/Alaskan				
	Native	4 (0.2)	1 (0.3)	3 (0.6)	0 (0.0)
	Native Hawaiian or				
	Pacific Islander	11 (0.6)	1 (0.3)	0 (0.0)	0 (0.0)
	Multiracial	102 (5.7)	8 (2.7)	19 (4.1)	1 (1.2)
	Other	63 (3.5)	9 (3.0)	27 (5.8)	5 (6.1)
	Missing	24 (1.3)	8 (2.7)	8 (1.7)	0 (0.0)
H	lispanic: n (%)	100 (5.6)	33 (11.1)	28 (6.0)	10 (12.2)
Education Level: n					
(°	%)				
	Bachelor's Degree or				
	higher	1120 (62.6)	50 (16.8)	266 (57.3)	14 (17.1)
	Some college	395 (22.1)	79 (26.5)	106 (22.8)	16 (19.5)
	High school	404 (7.0)			
	graduate	131 (7.3)	57 (19.1)	39 (8.4)	13 (15.9)
	Did not finish high	107 (6.0)	78 (26.2)	40 (8.6)	32 (39.0)

school				
Don't know	12 (0.7)	15 (5.0)	4 (0.9)	5 (6.1)
Missing	23 (1.3)	19 (6.4)	9 (1.9)	2 (2.4)
Employment Status: n				
(%)				
Working now	1208 (67.6)	108 (36.2)	342 (73.7)	23 (28.0)
Student	294 (16.4)	115 (38.6)	78 (16.8)	43 (52.4)
Retired	99 (5.5)	3 (1.0)	9 (1.9)	2 (2.4)
Unemployed	169 (9.5)	63 (21.1)	27 (5.8)	14 (17.1)
Other	7 (0.4)	4 (1.3)	2 (0.4)	0 (0.0)
Missing	11 (0.6)	5 (1.7)	6 (1.3)	0 (0.0)

Figure 1: Consort Diagram for DPSO and DPE Analyses





Figure 2: PCR and Rapid Antigen Test Positivity by Day Past Symptom Onset



Figure 3: PCR and Rapid Antigen Test Positivity by Day Past Exposure

13 14

13 14

64

32 32